Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RED FLASH study
NL-OMON59077Phase 3Recruiting
- Sponsor
- Reinier de Graaf Hospital
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of oxybutynin and venlafaxine in hot flash (2 arms), sponsored by Reinier de Graaf Hospital. Primary endpoint: Number and severity of hot flashes. Started Aug 2024; status: recruiting.
02
Drugs
oxybutyninvenlafaxine
03
Conditions
hot flash
Beyond the preview
Go deeper on NL-OMON59077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59077.